Race Oncology's new clinical trial initiative

Race Oncology (ASX:RAC) has filed a human ethics application for a Phase 1 clinical trial of its lead drug candidate, RC220 bisantrene. The trial will evaluate the drug's safety and efficacy in patients with solid tumors in Australia, with first patient recruitment expected in Q1 2025.

Overview and future prospects for Race Oncology

Race Oncology has announced the submission of a human ethics application for a Phase 1 clinical trial of RC220 bisantrene, aiming to assess its safety in combination with doxorubicin. This trial, set in Australia, is crucial for the company's strategy to develop cardioprotective anticancer therapies. It will be conducted in two stages to determine the maximum tolerated dose and evaluate the drug's efficacy. The trial's success could lead to broader Phase 2 studies across multiple regions, enhancing RC220’s development as a cardioprotective agent. Race Oncology collaborates with George Clinical and the Cancer Care Foundation for this initiative, with plans to expand to sites in Hong Kong and South Korea. The company is focused on advancing bisantrene, known for its anticancer benefits and safety, and is exploring partnerships to facilitate its global reach.

Executive insights on the clinical trial announcement

The submission of the human ethics application for our Phase 1 clinical trial of RC220 is a critical milestone in our strategy to develop safer and more effective cancer treatments.